Allergan Completes Acquisition of AqueSys
ALLERGAN has completed its acquisition of AqueSys, a devicemaker focused on the development of ocular implants that reduce intraocular pressure associated with glaucoma.
The transaction, valued at $300 million plus potential regulatory approval and commercialization milestone payments related to AqueSys’ XEN45, was announced in September.
XEN45 is a soft shunt used in minimally invasive glaucoma surgeries that facilitates aqueous fluid flow to lower intraocular pressure while protecting against the potential for hypotony associated with current subconjunctival procedures. It is implanted by ophthalmologists in the anterior chamber of the eye.
The product has received CE mark in the EU and is in late-stage development in the U.S. — Michael Cipriano